# "Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"

Source: https://onco.cc/trials/nct06829355/  
OnCo record `nct06829355` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of regorafenib and tislelizumab in colorectal cancer, run by Beijing Friendship Hospital, now recruiting.

## Summary

"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer" is a phase 2, randomised interventional study registered as NCT06829355 by Beijing Friendship Hospital, with a registry enrolment figure of 52 participants, started 2025-02-11 and due to reach its primary completion in 2025-12-31. Interventions recorded: Thymalfasin (Thymosin alpha 1, Ta1); Regorafenib (BAY 73-4506); Tislelizumab (BGB-A317). Conditions listed: MCRC. Primary outcome: Progression-free survival (PFS). Colorectal eligibility wording from the registry: "* Able to sign a written informed consent form (ICF) and able to understand and comply with the requirements of this study Male or female aged 18 to 75 Histologically or cytologically confirmed advanced or metastatic colorectal adenocarcinoma Mismatch repair (MMR) protein expression or microsatellit". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: THYMI
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06829355
- Phase: 2
- Setting: Efficacy and Safety Study of Thymalfasin in Combination with Targeted Immunotherapy (Regorafenib and Tislelizumab) in Patients with Advanced PMMR/MSS Colorectal Cancer Who Failed Standard of Care: a Multicenter, Open-label, Randomized, Controlled Clinical Study
- Sponsor: Beijing Friendship Hospital
- Enrolled: 52

## Sources

- ClinicalTrials.gov NCT06829355: https://clinicaltrials.gov/study/NCT06829355

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Regorafenib](https://onco.cc/drugs/regorafenib/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06829355.json